<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Extracted Document</title>
    <style>
        body { font-family: Arial, sans-serif; max-width: 900px; margin: 0 auto; padding: 20px; }
        h1, h2, h3 { color: #333; }
        .page { margin-bottom: 50px; border-bottom: 2px solid #ccc; padding-bottom: 30px; }
        .title { font-size: 1.3em; font-weight: bold; margin: 20px 0; }
        .text { margin: 15px 0; line-height: 1.6; }
        .figure { margin: 20px 0; text-align: center; }
        .figure img { max-width: 100%; height: auto; border: 1px solid #ddd; }
        .figure-caption { font-style: italic; color: #666; margin-top: 10px; }
        .metadata { background: #f5f5f5; padding: 15px; margin-top: 30px; }
    </style>
</head>
<body>

<h1>Extracted Document</h1>
<p><strong>Source:</strong> data/clinical_files/FlublokPI.pdf</p>
<p><strong>Total Pages:</strong> 5</p>
<hr>
<div class="page">
<h2>Page 1</h2>
<div class="text">5.2 Guillain Barré Syndrome<br>If GBS has occurred within 6 weeks of receipt of a prior inﬂuenza vaccine, the deci<br>togiveFlublokshouldbebasedoncareful considerationof thepotential beneﬁtsandr<br>The 1976 swine inﬂuenza vaccine was associated with an increased frequenc<br>Guillain-BarréSyndrome(GBS). Evidenceforacausal relationof GBSwithotherinﬂue<br>vaccines is inconclusive; if an excess risk exists, it is probably slightly more than</div>
<div class="text">Description (11)].<br>5<br>WARNINGS AND PRECAUTIONS<br>5.1 Managing Allergic Reactions<br>Appropriate medical treatment must be immediately available to manage potentia</div>
<div class="text">g<br>dminister Flublok as a single 0.5 mL dose.<br>2 Administration</div>
<div class="figure">
<img src="figures/table_p1_6addbadb.png" alt="[TABLE 4 - See table_p1_6addbadb.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 4 - See table_p1_6addbadb.png]</div>
</div>
<div class="title">2
DOSAGE AND ADMINISTRA
2.1
Dosage</div>
<div class="text">FULL PRESCRIBING INFORMATION: CONTENTS*<br>1<br>INDICATIONS AND USAGE<br>DOSAGE AND ADMINISTRATION</div>
<div class="text">————————————<br>CONTRAINDICATIONS<br>————————————<br>• Do not administer Flublok to anyone with a history of severe allergic reactions<br>(e.g., anaphylaxis) to any component of the vaccine. (4, 6.2, 11)<br>——————————<br>WARNINGS AND PRECAUTIONS<br>——————————</div>
<div class="text">or intramuscular use (0.5 mL). (2)<br>—————————<br>DOSAGE FORMS AND<br>ublok is an injection a single dose is 05mL</div>
<div class="text">vaccine. Flublok is approved for use in persons 18 years of age and older. (1)<br>——————————<br>DOSAGE AND ADMINISTRATION<br>——————————<br>For intramuscular use (05 mL) (2)</div>
<div class="text">Initial U.S. Approval: 2013<br>———————————<br>INDICATIONS AND USAGE<br>———————————<br>Flublok is a vaccine indicated for active immunization for the prevention of disease</div>
<div class="text">HIGHLIGHTS OF PRESCRIBING INFORMATION<br>Thesehighlightsdonot includeall theinformationneededtouseFlublok®safely<br>and effectively. See full prescribing information for Flublok.<br>Flublok (Inﬂuenza Vaccine)<br>njection for Intramuscular Use 2024-2025 Formula</div>
<div class="text">data for Flublok are presented fromfour clinical trials (Studies 1, 2, 3, and 4). Data<br>a placebo-controlled trial in adults 18 through 49 years of age (Study 1) are<br>nted, followed by data pooled according to age group fromStudies 2 and 4 (adults<br>ough 64 years of age) and Studies 3 and 4 (adults aged 65 years and older).</div>
<div class="title">y
hrough 64 years of age, a
i
d
l
b
ti</div>
<div class="text">ults 65 years of age and older, the most common (≥10%) injection site adverse<br>on was pain (19%); the most common (≥10%) solicited systemic adverse reactions<br>fatigue (13%) and headache (10%). (6.1)<br>Clinical Trials Experience<br>use clinical studies are conducted under widely varying conditions, adverse reaction<br>observed in the clinical studies of a vaccine cannot be directly compared to rates<br>e clinical studies of another vaccine and may not reﬂect the rates observed in clinica<br>ce.<br>safety experience with Flublok Quadrivalent is relevant to Flublok because both<br>nes are manufactured using the same process and have overlapping compositions.<br>ok<br>ok has been administered to and safety data collected from2497 adults 18 through</div>
<div class="text">re headache (15%), fatigue (15%) and muscle pain (11%). (6.1)<br>adults 50 through 64 years of age, the most common (≥10%) injection site adverse<br>ction was pain (32%); the most common (≥10%) solicited systemic adverse reactions<br>re headache (17%), fatigue (13%), and muscle pain (11%). (6.1)</div>
<div class="text">adults 18 through 49 years of age, the most commo<br>ction was pain (37%); the most common (≥10%) solic</div>
<div class="text">ection-site adverse</div>
<div class="text">• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior<br>inﬂuenza vaccine, the decision to give Flublok should be based on careful<br>consideration of potential beneﬁts and risks. (5.2)<br>————————————<br>ADVERSE REACTIONS<br>————————————<br>• In adults 18 through 49 years of age, the most common (≥10%) injection-site<br>adverse reaction was pain (37%); the most common (≥10%) solicited systemic<br>adverse reactions were headache (15%), fatigue (15%) and muscle pain (11%).<br>(6.1)<br>• In adults 50 through 64 years of age, the most common (≥10%) injection site<br>adverse reaction was pain (32%); the most common (≥10%) solicited systemic<br>adverse reactions were headache (17%), fatigue (13%), and muscle pain (11%).<br>(6.1)<br>• In adults 65 years of age and older, the most common (≥10%) injection site<br>adverse reaction was pain (19%); the most common (≥10%) solicited systemic<br>adverse reactions were fatigue (13%) and headache (10%). (6.1)<br>To report SUSPECTED ADVERSE REACTIONS, contact SanoﬁPasteur Inc., at<br>(1-800-822-2463<br>(1-800-Vaccine)<br>or<br>VAERS<br>at<br>1-800-822-7967<br>or<br>www.vaers.hhs.gov.<br>See 17 for PATIENT COUNSELING INFORMATION<br>Revised: 07/2024<br>8<br>USE IN SPECIFIC POPULATIONS<br>8.1<br>Pregnancy<br>8.2<br>Lactation<br>8.4<br>Pediatric Use</div>
</div>
<div class="page">
<h2>Page 2</h2>
<div class="text">Nausea<br>6<br>1<br><1<br>5<br>1<br><1<br>Joint pain<br>4<br><1<br><1<br>4<br><1<br><1<br>Chills<br>3<br><1<br><1<br>3<br><1<br><1<br>Fever¶<br><1<br><1<br><1<br><1<br><1<br><1<br>NOTE: Data based on the most severe response reported by subjects. Results ≥1%<br>reported to nearest whole percent; results >0 but <1% reported as <1%.<br>*Total VaccinatedCohort isdeﬁnedasall randomizedsubjectswhoreceivedstudyvaccine<br>according to the treatment actually received and who provided data.<br>†Study 1 is registered as NCT00539981 under the National Clinical Trials registry.<br>‡Denominators for Study 1: The total number of enrolled, randomized, and vaccinated<br>subjectswas2344intheFlublokgroupand2304intheplacebogroup. For all categories<br>except fever, the number of subjects with missing values was 72 in the Flublok group<br>and73inthePlacebogroupsothat thesedenominatorsare2272and2231respectively.<br>For fever, 89 Flublok recipients and 104 Placebo recipients were missing data, making<br>these denominators 2255 and 2200 respectively.<br>§Moderate=hadit, andit was badenoughtoprevent asigniﬁcant part of usual activities;<br>Severe = had it, and it prevented most or all of normal activities, or had to see a doctor<br>for prescription medicine.<br>¶Fever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F to<br><102.2°F); Severe (≥102.2°F)<br>Across three clinical trials (Studies 2 – 4, Tables 2 and 3) a total of 2050 adults age 50<br>years and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated<br>inﬂuenza vaccine (IIV3) comparator. The mean age of Flublok study participants was 65<br>years; 56% were female and 80% were Caucasian.<br>The incidence of solicited reactogenicity differed between adults 50 through 64 years of<br>age and adults aged 65 years and older. Therefore, data from Studies 2, 3, and 4 were<br>pooled according to age group and are presented separately (Tables 2 and 3).<br>M t d<br>ti<br>i b th<br>ild i<br>it</div>
<div class="text">Fatigue<br>15<br>3<br><1<br>14<br>3<br><1<br>Muscle Pain<br>11<br>2<br><1<br>7<br><1<br><1</div>
<div class="figure">
<img src="figures/table_p2_2b8fbd07.png" alt="[TABLE 3 - See table_p2_2b8fbd07.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 3 - See table_p2_2b8fbd07.png]</div>
</div>
<div class="text">endpoint.<br>Study 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety<br>analysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinical<br>Studies [14.1]).<br>Study 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety<br>analysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent<br>inﬂuenza vaccine (Fluzone, manufactured by SanoﬁPasteur, Inc.) as an active control<br>(n=302) (2).<br>Study 3 (NCT00395174) included 869 subjects aged 65 years and older for safety<br>analysis, randomized to receive Flublok (n=436) or another U.S.-licensed trivalent<br>inﬂuenza vaccine (Fluzone) as an active control (n=433) (3).<br>Study 4 (NCT01825200) included 2627 subjects aged 50 years and older for safety<br>analysis, randomized to receive Flublok (n=1314) or another U.S.-licensed trivalent<br>inﬂuenzavaccine(Aﬂuria, manufacturedbybioCSLPtyLtd.)asanactivecontrol (n=1313).</div>
<div class="text">ays following receipt of vaccine. Study 4 also actively solicited pre speciﬁed common<br>iti it t<br>ti<br>th<br>h 30 d<br>f ll<br>i<br>i t f<br>i<br>i</div>
<div class="text">of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were<br>collected for 28-30 days post-vaccination. In Studies 1- 3 and 5, SAEs were collected for<br>6 months post-vaccination via clinic visit or telephone follow up on Day 28, telephone<br>ollow up on Day 180 or by spontaneous reporting Study 4 collected SAEs through 30</div>
<div class="text">Reactogenicity data froma small Phase 2 trial (Study 5) in adults 18 through 49 years of<br>age, 153 of whom received Flublok 135mcg, are not presented. However, subjects from<br>Study 5 are included in the description of deaths and serious adverse events (SAEs). In<br>all st dies local (injectionsite) ands stemic ad ersereactions eresolicited iththe se</div>
<div class="text">r prescription medicine.<br>ever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°<br>102.2°F); Severe (≥102.2°F)</div>
<div class="figure">
<img src="figures/table_p2_fd1f0997.png" alt="[TABLE 9 - See table_p2_fd1f0997.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 9 - See table_p2_fd1f0997.png]</div>
</div>
<div class="text">Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and<br>Systemic Adverse Reactions within 7 Days of Administration of Flublok or<br>Comparator in Adults ≥65 Years of Age, Studies 3 and 4, Total Vaccinated<br>Cohort *,†<br>Flublok<br>N=1078<br>IIV3†<br>N=1081<br>Any<br>Mod‡<br>Sev‡<br>Any<br>Mod‡<br>Sev‡<br>Local<br>%<br>Pain<br>19<br><1<br><1<br>20<br><1<br><1<br>Redness<br>7<br>1<br><1<br>7<br>1<br>1<br>Firmness/Swelling<br>7<br>2<br><1<br>7<br><1<br><1</div>
<div class="text">r prescription medicine.<br>ever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F<br>102.2°F); Severe(≥102.2°F) For fever, 12Flublokrecipientsand5IIV3recipientsw<br>issing data, making these denominators 964 and 962, respectively.</div>
<div class="figure">
<img src="figures/table_p2_72d32c35.png" alt="[TABLE 12 - See table_p2_72d32c35.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 12 - See table_p2_72d32c35.png]</div>
</div>
<div class="text">Flublok<br>N=972<br>IIV3†<br>N=967<br>Any<br>Mod‡<br>Sev‡<br>Any<br>Mod‡<br>Sev‡<br>Local<br>%<br>Pain<br>32<br>2<br><1<br>37<br><1<br>0<br>Firmness/Swelling<br>7<br>2<br><1<br>6<br>1<br><1<br>Redness<br>6<br>2<br><1<br>5<br>1<br><1</div>
</div>
<div class="page">
<h2>Page 3</h2>
<div class="text">y<br>g<br>,<br>q<br>y<br>p<br>(Flublok 1.3%, IIV3 0.8%) over the 30 day follow-up period.<br>Flublok Quadrivalent<br>FlublokQuadrivalent hasbeenadministeredtoandsafetydatacollectedfrom4328adults<br>50 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).<br>SAEs were collected for 6 months post-vaccination via clinic visit or remote contact.<br>Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to<br>receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by<br>GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis<br>population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine<br>recipients. The mean age of participants was 62.7 years. Overall, 58%of subjects were<br>female, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/<br>Alaskan Native, 0.4% Asian, 0.2% Native Hawaiian/Paciﬁc Islander, 0.7% other racial<br>groups, and 5% of Hispanic/Latino ethnicity.<br>Amongadults50yearsof ageandolder (Study6), therewerenoSAEsconsideredrelated<br>to study vaccine.<br>Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to<br>receive Flublok Quadrivalent or a Comparator inactivated inﬂuenza vaccine (Fluarix®<br>Quadrivalent, manufacturedby GlaxoSmithKline). Thesafety analysis populationincluded<br>998recipients of Flublok Quadrivalent and332Comparator vaccinerecipients. Themean<br>age of participants was 33.5 years. Overall, 65% of subjects were female, 59%<br>white/Caucasian, 37% black/African American, 1.0% Native Hawaiian/Paciﬁc Islander,<br>0.8%American Indian/Alaskan Native, 0.5%Asian, 1.4%other racial groups, and 16%of<br>Hispanic/Latino ethnicity.<br>Amongadults18-49yearsof age(Study7), through6monthspost-vaccination, therewere<br>no SAEs considered related to study vaccine.<br>1NCT02285998<br>2NCT02290509<br>6.2 Postmarketing Experience<br>The following events have been spontaneously reported during post approval use of<br>Flublok or Flublok Quadrivalent. They aredescribedbecauseof thetemporal relationship,<br>the biologic plausibility for a causal relationship to Flublok or Flublok Quadrivalent, and<br>their potential seriousness. Because these events are reported voluntarily from a<br>population of uncertain size, it is not always possible to reliably estimate their frequency<br>or establish a causal relationship to vaccine exposure.<br>Immune system disorders: anaphylaxis, allergic reactions, and other forms of hypersen-<br>sitivity (including urticaria).<br>Nervous system disorders: facial palsy (Bell’s palsy), Guillain-Barré syndrome, syncope.<br>8<br>USE IN SPECIFIC POPULATIONS<br>8.1 Pregnancy<br>Pregnancy Exposure<br>There is a pregnancy exposure registry that monitors pregnancy outcomes in women<br>exposed to Flublok.<br>Healthcare providers are encouraged to enroll women who receive Flublok during<br>pregnancy in SanoﬁPasteur Inc.’s vaccination pregnancy registry by calling 1-800-822-<br>2463.<br>Risk Summary<br>All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S.<br>general population, theestimatedbackgroundrisks of major birthdefects andmiscarriage<br>inclinicallyrecognizedpregnanciesare2%to4%and15%to20%, respectively.Available<br>dataonFlublokandFlublokQuadrivalent administeredtopregnant womenarelimitedand<br>insufficient to inform vaccine-associated risks in pregnant women.<br>A developmental study of Flublok has been performed in rats administered 05 mL</div>
<div class="title">1.9%and 0.9%
7d
f ll
i</div>
<div class="title">activelysolicited
1.6%of IIV3 rec</div>
<div class="text">occurring in 1%-2% of subjects, were nasopharyngitis, upper respiratory infection,<br>headache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea.<br>Among adults 50-64 years of age (Studies 2 and 4 pooled), the most frequent unsolicited<br>adverseevents, occurringin1%of subjects, werediarrheaandcough.Amongadults≥65<br>years of age (Studies 3 and 4 pooled), the most frequent unsolicited adverse events,<br>occurring in 1% of subjects, were nasopharyngitis and cough.<br>Among adults 50 years of age and older (Study 4) for whom the incidence of rash,<br>urticaria, swelling, non- pitting edema, or other potential hypersensitivity reactions were</div>
<div class="text">p<br>j<br>,<br>p<br>,<br>p<br>onsidered related to the study vaccines.<br>n Study 1 (adults 18-49 years of age), the most frequent unsolicited adverse events<br>i<br>i<br>1%2%<br>f<br>bj<br>h<br>i i<br>i<br>i f<br>i</div>
<div class="text">subjects, 6 Flublok recipients and 4 IIV3 recipients. One of the SAEs, vasovagal syncope<br>following injection of Flublok, was considered related to administration of study vaccine.<br>A<br>d lt 65<br>f<br>d ld<br>(St di<br>3<br>d4<br>l d) th<br>h<br>t 6<br>th</div>
<div class="text">p<br>y<br>g<br>either was consideredvaccine-related. SAEs werereportedby 32Flublok recipients and<br>5 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related<br>o the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No<br>peciﬁc cause was identiﬁed. The patient recovered.<br>Among adults 50 64 years of age (Studies 2 and 4 pooled) through up to 6 months or</div>
<div class="text">mong adults 18-49 years of age (Studies 1 and 5 pooled), through 6 months<br>ost-vaccination, two deaths were reported, one in a Flublok recipient and one in a<br>acebo recipient Both deaths occurred more than 28 days following vaccination and</div>
<div class="title">headache, chills/sweats
and throat swab sampl</div>
<div class="text">was assessed by active and passive surveillance for inﬂuenza like illness (ILI) beginning<br>2 weeks post-vaccination until the end of the inﬂuenza season, approximately 7 months<br>post- vaccination. ILI was deﬁned as having at least 2 of 3 symptoms (no speciﬁed<br>duration) in the following categories: 1) fever ≥100°F; 2) respiratory symptoms (cough,<br>sore throat, or runny nose/stuffy nose); or 3) systemic symptoms (myalgias, arthralgias,<br>headache chills/sweats or tiredness/malaise) For subjects with an episode of ILI nasal</div>
<div class="text">n the U.S. during the 2007 2008 inﬂuenza season in adults 18 49 years of age (Study<br>1). (1)<br>Study 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years) randomized<br>n a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304)<br>Among enrolled subjects, 59%were female, 67%were white, 19%African-American, 2%<br>Asian, < 1%otherraces, and11%of Latino/Hispanicethnicity. Culture-conﬁrmedinﬂuenza</div>
<div class="text">13<br>NONCLINICAL TOXICOLOGY<br>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility<br>Flublok has not been evaluated for carcinogenic or mutagenic potential, or for impairment<br>of male fertility in animals.<br>14<br>CLINICAL STUDIES<br>14.1 Efficacy Against Laboratory-Conﬁrmed Inﬂuenza<br>The efficacy of Flublok in protecting against culture-conﬁrmed inﬂuenza illness was</div>
<div class="text">( )<br>y)<br>Antibodies against one inﬂuenza virus type or subtype confer limited or no protection<br>against another. Furthermore, antibodies to one antigenic variant of inﬂuenza virus might<br>not protect against a new antigenic variant of the same type or subtype. Frequent<br>development of antigenicvariantsthroughantigenicdrift isthevirologicbasisfor seasonal<br>epidemicsandthereasonfor theusual replacement of oneor moreinﬂuenzavirusstrains<br>in each year’s inﬂuenza vaccine.<br>G</div>
<div class="text">syringes contain no natural rubber latex.<br>12<br>CLINICAL PHARMACOLOGY<br>12.1 Mechanism of Action<br>Flublok contains recombinant HAproteins of the three strains of inﬂuenza virus speciﬁed<br>by health authorities for inclusion in the annual seasonal vaccine. These proteins function<br>as antigens which induce a humoral immune response, measured by hemagglutination<br>hibiti<br>(HI)<br>tib d )</div>
<div class="text">requirements. For the2024-2025inﬂuenzaseasonit is formulatedtocontain135mcgHA<br>per 0.5mLdose, with45mcgHAof eachof thefollowing3inﬂuenzavirusstrains:A/West<br>Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/<br>2022 (H3N2) and B/Austria/1359417/2021.<br>A single 0.5 mL dose of Flublok contains sodium chloride (4.4 mg), monobasic sodium<br>phosphate (0.2 mg), dibasic sodiumphosphate (0.5 mg), and polysorbate 20 (Tween®20)<br>(27.5mcg). Each0.5mLdoseof Flublokmayalsocontainresidual amountsof baculovirus<br>andSpodopterafrugiperdacell proteins (≤14.3mcg), baculovirus andcellular DNA(≤10<br>ng), and Triton X-100 (≤100 mcg).<br>Flublok contains no egg proteins, antibiotics, or preservatives. The single-dose, preﬁlled<br>i<br>t i<br>t<br>l<br>bb<br>l t</div>
<div class="text">xpressed in this cell line using a baculovirus vector (Autographa californica nuclear<br>olyhedrosis virus), extracted from the cells with Triton X-100 and further puriﬁed by<br>olumn chromatography. The puriﬁed HAs are then blended and ﬁlled into single-dose<br>yringes.<br>Flublok is standardized according to United States Public Health Service (USPHS)</div>
<div class="text">[<br>]<br>j<br>g<br>hemagglutinin(HA) proteinsfromthreeinﬂuenzavirusesfor intramuscular use. It contains<br>puriﬁedHAproteins producedinacontinuous insect cell line(expresSF+®) that is derived<br>rom Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths,<br>caterpillars and butterﬂies), and grown in serum-free medium composed of chemically-<br>deﬁned lipids, vitamins, amino acids, and mineral salts. Each of the three HAs is</div>
<div class="text">manufactured using the same process and have overlapping compositions.<br>1<br>DESCRIPTION<br>Flublok [Inﬂuenza Vaccine] is a sterile, clear, colorless injection containing recombina</div>
<div class="text">8.5 Geriatric Use<br>Data froman efficacy study (Study 6), which included 1759 subjects ≥65 years and 525<br>subjects ≥75 years who received Flublok Quadrivalent, are insufficient to determine<br>whether elderly subjects respond differently from younger subjects (See Clinical Studies</div>
<div class="text">Data froma randomized, controlled trial demonstrated that children 6 months to less than<br>years of age had diminished hemagglutinin inhibition (HI) responses to Flublok<br>omparedtoaU.S.-licensedinﬂuenzavaccineapprovedforuseinthispopulation, strongly<br>uggestingthat Flublok wouldnot beeffectiveinchildrenyounger than3years of age(6).<br>Safety and effectiveness of Flublok have not been established in children 3 years to less<br>han 18 years of age.</div>
<div class="text">The developmental and health beneﬁts of breastfeeding should be considered along wit<br>the mother’s clinical need for Flublok and any potential adverse effects on the breastfe<br>child fromFlublok or fromthe underlying maternal condition. For preventive vaccines, th<br>underlying condition is susceptibility to disease prevented by the vaccine</div>
<div class="title">the effects of Flublok on the breastfed infant or on milk pr</div>
<div class="text">evelopment or female fertility were observed in the study.<br>.2 Lactation<br>isk Summary<br>isnot knownwhether Flublokisexcretedinhumanmilk Dataarenot availabletoassess</div>
<div class="text">Clinical Considerations<br>Disease-associated Maternal and/or Embryo/Fetal Risk<br>Pregnant womenareat increasedriskof complicationsassociatedwithinﬂuenzainfection<br>compared to non-pregnant women. Pregnant women with inﬂuenza may be at increased<br>risk for adverse pregnancy outcomes, including preterm labor and delivery.<br>Data<br>Animal<br>In a developmental toxicity study, female rats were administered Flublok by intramuscular<br>injectiontwiceprior tomating(35days and14days prior tomating) andongestationDay<br>6. The total dose was 0.5 mL (divided) on each occasion (a human dose is 0.5 mL). No<br>vaccine-related fetal malformations or variations and no adverse effects on pre-weaning</div>
</div>
<div class="page">
<h2>Page 4</h2>
<div class="text">The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-deﬁned ILI due to<br>any strain of inﬂuenza. Attack rates and relative vaccine efficacy (rVE), deﬁned as 1 –<br>[Attack rate Flublok Quadrivalent/ Attack Rate Comparator], were calculated for the total<br>efficacy population (n=8604) for the primary efficacy endpoint and for several alternative<br>efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity<br>(″matching″) of clinical isolates to vaccine antigens were not performed. CDC epidemio-<br>logical data for the 2014-2015 inﬂuenza season indicated that InﬂuenzaA(H3N2) viruses</div>
<div class="text">reaction(rtPCR) -conﬁrmedinﬂuenzawasassessedbyactiveandpassivesurveillancefo<br>nﬂuenza-likeillness(ILI)beginning2weekspost-vaccinationuntil theendof theinﬂuenza<br>season, approximately 6months post- vaccination. ILI was deﬁnedas havingat least one<br>symptom (no speciﬁed duration) in each of two categories of respiratory and systemic<br>symptoms. Respiratory symptoms included sore throat, cough, sputum production<br>wheezinganddifficultybreathing. Systemicsymptomsincludedfever > 99°F(>37°C) oral<br>chills, fatigue, headache and myalgia. For subjects with an episode of ILI, a nasopha<br>ryngeal swab sample was collected for rtPCR testing and reﬂex viral culture of rtPCR<br>positive samples.</div>
<div class="figure">
<img src="figures/figure_p4_8dd0145f.png" alt="[FIGURE 3 - See figure_p4_8dd0145f.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 3 - See figure_p4_8dd0145f.png]</div>
</div>
<div class="text">atc ed st a s<br>995)<br>Any ILI, all<br>matched strains¶,#<br>2<br>0.1<br>6<br>0.3<br>67.2<br>(-83.2,<br>96.8)<br>Positive culture with any strain, regardless of match to the vaccine<br>CDC-ILI, all<br>strains‡,Þ<br>44<br>1.9<br>78<br>3.4<br>44.6<br>(18.8, 62.6)<br>Sub-Type A<br>26<br>1.1<br>56<br>2.4<br>54.4<br>(26.1, 72.5)<br>Type B<br>18<br>0.8<br>23<br>1.0<br>23.1<br>(-49.0,<br>60.9)<br>Any ILI all strains¶<br>64<br>27<br>114<br>49<br>448<br>(244 600)</div>
<div class="text">Positive culture with a strain represented in the vaccine<br>CDCILI all<br>1<br>004<br>4<br>02<br>754<br>( 1480</div>
<div class="text">Case deﬁnition<br>Flublok<br>(N=2344)<br>Saline<br>Placebo<br>(N=2304)<br>Flublok<br>Vaccine<br>Efficacy†,<br>%<br>95%<br>Conﬁdence<br>Interval<br>Cases,<br>n<br>Rate,<br>%<br>Cases,<br>n<br>Rate,<br>%</div>
<div class="text">6 8)<br>The pre-deﬁned success criterion for the primary efficacy analysis was that the lowe<br>bound of the 95%conﬁdence interval (CI) of VEshould be at least 40%. Vaccine efficacy<br>against antigenically matched culture-conﬁrmed CDC-ILI could not be determined reliably<br>because 96% of the inﬂuenza isolates obtained from subjects in Study 1 were not<br>antigenically matched to the strains represented in the vaccine. An exploratory analysis<br>of VE of Flublok against all strains, regardless of antigenic match, isolated from any<br>ubject with an ILI, not necessarily meeting CDC- ILI criteria, demonstrated an efficacy<br>estimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case<br>deﬁnition and antigenic similarity.<br>Table 4: Vaccine Efficacy Against Culture-Conﬁrmed Inﬂuenza in Healthy<br>Adults 18-49 Years of Age, Study 1*</div>
<div class="text">The primary efficacy endpoint of Study 1 was Centers for Disease Control-deﬁned<br>nﬂuenza-like illness (CDC-ILI) with a positive culture for an inﬂuenza virus strain<br>antigenically resembling a strain represented in Flublok. CDC-ILI is deﬁned as fever of<br>≥100°F oral accompanied by cough, sore throat, or both on the same day or on<br>consecutive days. Attack rates and vaccine efficacy (VE), deﬁned as the reduction in the<br>nﬂuenzarateforFlublokrelativetoplacebo,werecalculatedforthetotal vaccinatedcohort<br>n=4648)</div>
<div class="text">17<br>PATIENT COUNSELING INFORMATION<br>Informthe vaccine recipient of the potential beneﬁts and risks of vaccination with Flublok<br>Inform the vaccine recipient that:</div>
<div class="text">• Store refrigerated between 2° and 8°C (36° and 46°F).<br>• Do not freeze. Discard if product has been frozen.<br>• Protect syringes from light.<br>• Do not use after expiration date shown on the label.</div>
<div class="figure">
<img src="figures/figure_p4_6c20804c.png" alt="[FIGURE 11 - See figure_p4_6c20804c.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 11 - See figure_p4_6c20804c.png]</div>
</div>
<div class="text">§<br>y<br>distinguished by lineage.<br>¶Culture of rtPCR-positive samples was performed in MDCK cells.<br>15<br>REFERENCES<br>1. Treanor JJ, El Sahly HM, King J, et. al. Protective efficacy of a trivalent recombinant<br>hemagglutininproteinvaccine(FluBlok) against inﬂuenzainhealthyadults: arandomized,<br>placebo-controlled trial. Vaccine. 2011, Vol. 29, pp. 7733-7739.<br>2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and<br>mmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin<br>nﬂuenza vaccine administered intramuscularly to healthy adults 50-64 years of age.<br>Vaccine. 2011, Vol. 29, pp. 2272-2278.<br>3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recom-<br>binant inﬂuenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among<br>persons ≥65 years old. Vaccine. 2009, Vol. 28, pp. 379-385.<br>4. Izikson R, Leffell DJ, Bock SA, et. al. Randomized comparison of the safety of<br>Flublok®versus licensed inactivated inﬂuenza vaccine in healthy, medically stable adults<br>≥50years of age. Vaccine. 2015, Vol. 33, pp. 6622–6628.<br>5. TreanorJJ, Schiff GM, HaydenFG, et.al. Safetyandimmunogenicityof abaculovirus-<br>expressed hemagglutinin inﬂuenza vaccine: a randomized controlled trial. JAMA. 2007,<br>Vol. 297, pp. 1577-1582.</div>
<div class="text">Inﬂuenza<br>96<br>2.2<br>138<br>3.2<br>0.70<br>30 (10, 47)<br>All rtPCR-positive<br>Inﬂuenza A§<br>73<br>1.7<br>114<br>2.7<br>0.64<br>36 (14, 53)<br>All rtPCR-positive<br>Inﬂuenza B§<br>23<br>0.5<br>24<br>0.6<br>0.96<br>4 (-72, 46)<br>All Culture-conﬁrmed<br>Protocol- deﬁned ILI§,¶<br>58<br>1.3<br>101<br>2.3<br>0.57<br>43 (21, 59)<br>Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.-<br>icensedquadrivalent inactivatedinﬂuenzavaccine, FluarixQuadrivalent, manufacturedby<br>GlaxoSmithKline; n=number of inﬂuenzacases; N=number of subjectsintreatment group;<br>RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) × 100].<br>*Study 6 is registered as NCT02285998.<br>†Efficacy Population included all randomized subjects who received study vaccine and<br>providedanyfollow-updocumentationfor inﬂuenza-likeillnessbeginningat least 14days<br>post-vaccination. Excluded subjects with protocol deviations that could adversely affect<br>efficacy.<br>‡Primary Analysis. All cases of rtPCR-conﬁrmed inﬂuenza are included. Antigenic char-<br>acterizationandgeneticsequencingtodeterminesimilarityof isolatestovaccineantigens<br>were not performed. CDC surveillance data indicated that the majority of inﬂuenza<br>A/H3N2 wild type viruses were antigenically distinct whereas inﬂuenzaA/H1N1 and type<br>B viruses were antigenically similar to vaccine antigens during the 2014-2015 season.<br>Study 6 met the pre-speciﬁed success criterion for the primary endpoint (lower limit of<br>the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator<br>should be not less than - 20%)</div>
<div class="figure">
<img src="figures/table_p4_7de271e8.png" alt="[TABLE 14 - See table_p4_7de271e8.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 14 - See table_p4_7de271e8.png]</div>
</div>
</div>
<div class="page">
<h2>Page 5</h2>
</div>
<div class="metadata">
<h3>Extraction Metadata</h3>
<p>Text blocks: 62</p>
<p>Figures/Tables: 7</p>
</div>

</body>
</html>
